"The voice for cancer physicians and their patients in Massachusetts."

FDA Approves abiraterone acetate in combination with prednisone for high-risk CSPC

08 Feb 2018 2:12 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved abiraterone acetate (Zytiga, Janssen Biotech, Inc.) tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer (CSPC). Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software